Solpadeine (Tablets) Instructions for Use
ATC Code
N02BE51 (Paracetamol in combination with other drugs, excluding psycholeptics)
Active Substances
Caffeine (Ph.Eur.)
Paracetamol (Rec.INN)
Clinical-Pharmacological Group
Analgesic-antipyretic
Pharmacotherapeutic Group
Analgesics; other analgesics and antipyretics; anilides
Pharmacological Action
A combined medicinal product.
Paracetamol is an analgesic-antipyretic. It has analgesic, antipyretic, and weak anti-inflammatory effects. The mechanism of action is associated with the inhibition of prostaglandin synthesis, with a predominant effect on the thermoregulation center in the hypothalamus. The lack of effect on prostaglandin synthesis in peripheral tissues explains the absence of a negative effect on water-salt metabolism (sodium and water retention) and the gastrointestinal mucosa.
Caffeine stimulates the psychomotor centers of the brain, has an analeptic effect, enhances the effect of analgesics, eliminates drowsiness and fatigue, and increases physical and mental performance.
Pharmacokinetics
Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract, with relatively uniform distribution in body fluids. The binding of paracetamol to plasma proteins is minimal at therapeutic concentrations.
Paracetamol is metabolized in the liver and excreted in the urine as glucuronide and sulfate metabolites – less than 5% is excreted unchanged. The T1/2 after a therapeutic dose is 1-3 hours.
Caffeine is rapidly absorbed from the gastrointestinal tract and distributed throughout the body. Caffeine is almost completely metabolized in the liver by oxidation and demethylation into metabolites, which are excreted in the urine. The T1/2 is 4-9 hours.
Indications
Pain syndrome (mild to moderate): headache; migraine; bone pain; myalgia; neuralgia; arthralgia; dysmenorrhea; toothache.
Symptomatic treatment of colds, influenza, including febrile syndrome.
ICD codes
| ICD-10 code | Indication |
| G43 | Migraine |
| J06.9 | Acute upper respiratory infection, unspecified |
| J10 | Influenza due to identified seasonal influenza virus |
| K08.8 | Other specified disorders of teeth and supporting structures (including toothache) |
| M25.5 | Pain in joint |
| M79.1 | Myalgia |
| M79.2 | Neuralgia and neuritis, unspecified |
| N94.4 | Primary dysmenorrhea |
| N94.5 | Secondary dysmenorrhea |
| R50 | Fever of unknown origin |
| R51 | Headache |
| R52.0 | Acute pain |
| R52.2 | Other chronic pain |
| ICD-11 code | Indication |
| 1E30 | Influenza due to identified seasonal influenza virus |
| 8A80.Z | Migraine, unspecified |
| 8A8Z | Headache disorders, unspecified |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| DA0A.Z | Diseases of teeth and supporting structures, unspecified |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| FB56.2 | Myalgia |
| GA34.3 | Dysmenorrhea |
| LA30.5Z | Anomalies of tooth resorption or loss, unspecified |
| ME82 | Pain in joint |
| MG26 | Fever of other or unknown origin |
| MG30.Z | Chronic pain syndrome, unspecified |
| MG31.Z | Acute pain, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally with water.
For adults and adolescents over 12 years, take two tablets up to four times daily.
Maintain a minimum interval of 4 hours between doses.
Do not exceed the maximum daily dose of eight tablets.
The total duration of self-treatment without medical consultation must not exceed five days for pain and three days for fever.
The maximum overall treatment duration is ten days.
Adhere strictly to the recommended dosage to avoid the risk of serious liver damage from paracetamol overdose.
Reduce intake of other caffeine-containing beverages and foods during treatment.
Consult a physician if symptoms persist or if higher, more frequent, or prolonged dosing is required.
Adverse Reactions
Allergic reactions (skin rash, angioedema, urticaria), dyspeptic disorders (including nausea, epigastric pain).
In rare cases – hemolytic anemia, thrombocytopenia.
With long-term use in high doses – hepatotoxicity, nephrotoxicity, pancytopenia.
Contraindications
Severe hepatic and/or renal failure; epilepsy; arterial hypertension; glaucoma; sleep disorders; children under 12 years of age; hypersensitivity to the components of the combination.
With caution
Benign hyperbilirubinemias (including Gilbert’s syndrome), viral hepatitis, alcoholic liver disease, glucose-6-phosphate dehydrogenase deficiency, alcoholism.
Use in Pregnancy and Lactation
Should not be used during pregnancy and lactation (breastfeeding).
When taking caffeine, there is a high risk of having a child with low birth weight and a risk of spontaneous abortion.
Passing into breast milk, Caffeine can have a stimulating effect on the breastfed infant.
Use in Hepatic Impairment
Contraindicated in severe hepatic insufficiency.
Use in Renal Impairment
Contraindicated in severe renal insufficiency.
Pediatric Use
Contraindicated for use in children under 12 years of age.
Special Precautions
Excessive consumption of caffeine-containing products (coffee, tea) during treatment may cause overdose symptoms.
With long-term (more than 1 week) treatment, monitoring of peripheral blood counts and liver functional state is necessary. Without consulting a doctor, take for no more than 3 days for the treatment of febrile syndrome and no more than 5 days for pain syndrome.
May alter the results of doping control tests in athletes.
Makes diagnosis difficult in the “acute abdomen” symptom complex.
Patients suffering from atopic bronchial asthma and hay fever have an increased risk of developing allergic reactions.
During treatment, ethanol consumption should be avoided (increased risk of hepatotoxicity).
Drug Interactions
Enhances the effect of MAO inhibitors.
Reduces the effectiveness of uricosuric drugs.
Caffeine accelerates the absorption of ergotamine.
Under the influence of paracetamol, the elimination time of chloramphenicol increases 5 times.
With long-term use, Paracetamol may enhance the effect of anticoagulants (dicoumarol derivatives).
Concomitant use of paracetamol and ethanol increases the risk of hepatotoxic effects and acute pancreatitis.
Barbiturates, phenytoin, ethanol, rifampicin, phenylbutazone, tricyclic antidepressants and other inducers of microsomal oxidation increase the production of hydroxylated active metabolites, creating the possibility of severe intoxication with small overdoses.
Inhibitors of microsomal oxidation (cimetidine) reduce the risk of hepatotoxic action.
When used concomitantly, metoclopramide and domperidone increase, and cholestyramine decreases absorption.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Film-coated tablets, 65 mg+500 mg: 12 or 24 pcs.
Marketing Authorization Holder
Cheleon Rus, JSC (Russia)
Manufactured By
GlaxoSmithKline Dungarvan, Limited (Ireland)
Dosage Form
| Solpadeine Active | Film-coated tablets, 65 mg+500 mg: 12 or 24 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white, capsule-shaped with flat edges; on one side of the tablet, an embossed triangle symbol and “+” are printed.
| 1 tab. | |
| Caffeine | 65 mg |
| Paracetamol | 500 mg |
Excipients: corn starch – 41.4 mg, pregelatinized starch – 50 mg, povidone (K-25) – 2 mg, potassium sorbate – 0.6 mg, talc – 15 mg, stearic acid – 5 mg, croscarmellose sodium – 10 mg.
Film coating composition: hypromellose (HPMC, 6 cP) – 5 mg, triacetin – 1 mg.
Note: purified water is used in production, which is removed during the manufacturing process.
12 pcs. – blisters (1) – cardboard packs.
12 pcs. – blisters (2) – cardboard packs.
The secondary packaging may have a first-opening control feature.
Soluble tablets 65 mg+500 mg: 12 or 24 pcs.
Marketing Authorization Holder
Cheleon Rus, JSC (Russia)
Manufactured By
GlaxoSmithKline Dungarvan, Limited (Ireland)
Dosage Form
| Solpadeine Express | Soluble tablets 65 mg+500 mg: 12 or 24 pcs. |
Dosage Form, Packaging, and Composition
Soluble tablets white or almost white, round, flat-cylindrical, smooth, with a bevel and a score on one side.
| 1 tab. | |
| Caffeine (anhydrous) | 65 mg |
| Paracetamol | 500 mg |
Excipients: sodium bicarbonate – 1342 mg, citric acid (anhydrous) – 925 mg, sodium carbonate (anhydrous) – 134.2 mg, sorbitol – 50 mg, sodium saccharin – 10 mg, povidone (K-25) – 1 mg, dimethicone – 1 mg, sodium lauryl sulfate – 0.1 mg.
Note: purified water is used in production, which is removed during the manufacturing process.
4 pcs. – laminated strips (3) – cardboard packs.
4 pcs. – laminated strips (6) – cardboard packs.
The secondary packaging may have a first-opening control feature.
